Jeff Ehrhardt Joins Establishment Labs’ Executive Team

Establishment Labs Holdings Inc. has hired Jeff Ehrhardt as general manager of North America. One of his primary responsibilities will be to oversee the U.S. market launch of Motiva implants later this year. 

“Jeff is the ideal person to introduce Motiva to the United States,” Establishment Labs Founder/CEO Juan José Chacón-Quirós said. “Just as we have changed the standard for breast augmentation and reconstruction around the world for more than a decade, we will establish a new standard for women and plastic surgeons in the United States. With Jeff leading our efforts, we expect to become the leading technology not only in the U.S., but globally.”
 
Ehrhardt spent more than 25 years at Allergan Aesthetics, an Abbvie Company, most recently serving as general manager for Plastic Surgery and Regenerative Medicine. In that role, he was responsible for the company’s portfolio of implants and related technologies in breast augmentation and reconstruction, including developing and executing the group’s commercial strategy and managing the U.S. sales and marketing organizations. Ehrhardt has held numerous other positions at Allergan, including vice president of U.S. operations, vice president of sales, regional sales director, marketing director, sales training director, sales rep, and roles in business development. Prior to Allergan, Ehrhardt worked at American Cyanamid and Johnson & Johnson.

Ehrhardt received his bachelor’s degree in business from the University of Cincinnati and his MBA from Xavier University.
 
“Joining Establishment Labs is in many ways the culmination of the last 25 years of my career,” Ehrhardt commented. “I’ve seen firsthand the diminished importance of science and data in the U.S. market. The lack of innovation has left plastic surgeons with few, if any, real choices for technologies that can improve the outcomes of their breast procedures. Establishment Labs is different. The quality of the science and the outcomes achieved with Motiva implants are unprecedented. We will not only take share, but also have the potential to grow these markets as we show what can be achieved when a company puts women at the center of everything that it does.”
 
Establishment Labs’ Motiva silicone gel-filled implants are currently not approved for commercial distribution in the United States. The implants are undergoing PMA clinical investigation pursuant to U.S. Food and Drug Administration (FDA) regulations for investigational medical devices.
 
Establishment Labs Holdings Inc. is a global medtech firm dedicated to improving women’s health and wellness through the power of science, engineering, and technology. The company offers a portfolio of Femtech solutions for breast health, breast aesthetics and breast reconstruction. The company has delivered more than 3 million Motiva devices in over 85 countries since 2010. The Motiva Flora tissue expander is used to improve outcomes in breast reconstruction following breast cancer and it is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Mia Femtech, Establishment Lab’s minimally invasive experience for breast harmony, is the company’s most recent product. These solutions are supported by more than 200 patent applications in 25 separate patent families worldwide and over 50 scientific studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica. In 2018, the company received an investigational device exemption (IDE) from the FDA for Motiva Implants and began a clinical trial to support regulatory approval in the United States.